...
首页> 外文期刊>EMBO Molecular Medicine >Lysosomal dysfunction disrupts presynaptic maintenance and restoration of presynaptic function prevents neurodegeneration in lysosomal storage diseases
【24h】

Lysosomal dysfunction disrupts presynaptic maintenance and restoration of presynaptic function prevents neurodegeneration in lysosomal storage diseases

机译:溶酶体功能障碍破坏了突触前的维持,突触前功能的恢复阻止了溶酶体贮积病中的神经变性

获取原文
           

摘要

Abstract Lysosomal storage disorders (LSDs) are inherited diseases characterized by lysosomal dysfunction and often showing a neurodegenerative course. There is no cure to treat the central nervous system in LSDs. Moreover, the mechanisms driving neuronal degeneration in these pathological conditions remain largely unknown. By studying mouse models of LSDs, we found that neurodegeneration develops progressively with profound alterations in presynaptic structure and function. In these models, impaired lysosomal activity causes massive perikaryal accumulation of insoluble ???±-synuclein and increased proteasomal degradation of cysteine string protein ???± (CSP???±). As a result, the availability of both ???±-synuclein and CSP???± at nerve terminals strongly decreases, thus inhibiting soluble NSF attachment receptor (SNARE) complex assembly and synaptic vesicle recycling. Aberrant presynaptic SNARE phenotype is recapitulated in mice with genetic ablation of one allele of both CSP???± and ???±-synuclein. The overexpression of CSP???± in the brain of a mouse model of mucopolysaccharidosis type IIIA, a severe form of LSD, efficiently re-established SNARE complex assembly, thereby ameliorating presynaptic function, attenuating neurodegenerative signs, and prolonging survival. Our data show that neurodegenerative processes associated with lysosomal dysfunction may be presynaptically initiated by a concomitant reduction in ???±-synuclein and CSP???± levels at nerve terminals. They also demonstrate that neurodegeneration in LSDs can be slowed down by re-establishing presynaptic functions, thus identifying synapse maintenance as a novel potentially druggable target for brain treatment in LSDs.
机译:摘要溶酶体贮积症(LSDs)是一种以溶酶体功能障碍为特征的遗传性疾病,通常表现出神经变性过程。目前尚无治疗LSD中枢神经系统的方法。此外,在这些病理状况下驱动神经元变性的机制仍然是未知的。通过研究LSDs的小鼠模型,我们发现神经变性在突触前结构和功能的深刻改变中逐渐发展。在这些模型中,溶酶体活性的降低引起不溶性β-突触核蛋白的大量周向积累,并且半胱氨酸串蛋白β(CSPβ)的蛋白酶体降解增加。结果,在神经末梢的β-突触核蛋白和CSPβ均被大大降低,从而抑制了可溶性NSF附着受体(SNARE)复合物的组装和突触小泡的再循环。在小鼠中,通过CSP +和-+-突触核蛋白的一个等位基因的遗传消融,概括了异常的突触前SNARE表型。 LSP的一种严重形式的粘多糖贮积症IIIA型小鼠模型的大脑中CSP的过表达有效地重建了SNARE复合体装配,从而改善了突触前功能,减弱了神经退行性体征,并延长了生存期。我们的数据表明,与溶酶体功能障碍有关的神经变性过程可能是通过同时降低神经末梢的β-突触核蛋白和CSPβ-水平而突触地引发的。他们还证明,可以通过重新建立突触前功能来减缓LSD中的神经变性,从而将突触维持作为LSD中脑治疗的新型潜在药物靶点。

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号